Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tedizolid Tissue Penetration in Diabetic Wound Infections
NCT02620787Phase 1Completed
- Sponsor
- Hartford Hospital
- Start
- Feb 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tedizolid in Wound infection (WI) (2 arms), sponsored by Hartford Hospital. Primary endpoint: Tedizolid Tissue Penetration. Started Feb 2016; status: completed.
02
Drugs
tedizolid
03
Conditions
Wound infection (WI)
Beyond the preview
Go deeper on NCT02620787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02620787.